Maple Grove, MN –March 27, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of Fluoxetine Tablets, USP, 10 and 20 mg (the branded product: Prozac® * ). The product was approved by the U.S. Food and Drug Administration (FDA).
Fluoxetine Tablets, USP, 10 and 20 mg are prescribed for Major Depressive Disorder, Obsessive Compulsive Disorder, Bulimia Nervosa or Panic Disorder.
The 10 and 20 mg fluoxetine tablet market had U.S. sales of approximately $69 million for the 12 months ending December 2018 according to IQVIA.
* Prozac is a registered trademark of Eli Lilly and Company. Prozac® (fluoxetine) Tablets have been discontinued.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, do more good™ for the patients they serve. For more information, visit https://www.upsher-smith.com.